Nabla Bio raises $11M for an “end-to-end” antibody design platform
Announcing JAM-2: Drug-like antibodies straight from the computer
Technical ReportAnnouncing JAM-2: Drug-like antibodies straight from the computer
Technical ReportAnnouncing JAM-2: Drug-like antibodies straight from the computer
Technical ReportAnnouncing JAM-2: Drug-like antibodies straight from the computer
Technical ReportNabla Bio raises $11M for an “end-to-end” antibody design platform